Please provide your email address to receive an email when new articles are posted on . A: This 52-year-old man with presumed gastroesophageal reflux disease, erosive esophagitis grade D, is referred ...

While most potassium-competitive acid blockers demonstrate superior healing rates than proton pump inhibitors (PPIs) in patients with erosive esophagitis, both types of treatment offer relief compared ...

FLORHAM PARK, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for ...

The oral potassium-competitive acid blocker (PCAB) vonoprazan was noninferior and superior to the proton pump inhibitor (PPI) lansoprazole for erosive esophagitis, according to results of the phase 3 ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Scientists conducted a retrospective cohort study to examine the correlation of the shape and length of Barrett's epithelium with erosive esophagitis. They found that flame-like rather than lotus-like ...

Los Angeles, CA – New clinical data demonstrated, for the first time in a prospective study, a direct relationship between controlling gastric (or stomach) acid and healing erosive esophagitis caused ...

Phathom Pharmaceuticals PHAT stock jumped 8.42% on Tuesday after the company announced a positive outcome from a recent meeting with the FDA regarding the resubmission of its new drug application (NDA ...

Vonoprazan (Voquezna) was noninferior to lansoprazole (Prevacid) for healing patients with erosive esophagitis, and was superior for maintaining healing, a randomized trial showed. In a modified ...